In vivo neuroprotection by a creatine-derived compound: Phosphocreatine-Mg-complex acetate

Brain Research

Volumn 1285, Issue , 2009, Pages 158-163

  Perasso, L ^a   Adriano, E ^a   Ruggeri, P ^a   Burov, S V ^b   Gandolfo, C ^a   Balestrino, M ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b INSTITUTE OF MACROMOLECULAR COMPOUNDS   (Russian Federation)

Author keywords

Brain; Creatine; Ischemia; Neuroprotection; Stroke

Indexed keywords

CREATINE; CREATINE PHOSPHATE; CREATINE TRANSPORTER; DRUG VEHICLE; MAGNESIUM SULFATE; PHOSPHOCREATINE MAGNESIUM COMPLEX ACETATE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN INFARCTION; BRAIN ISCHEMIA; CAROTID ARTERY SURGERY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; HEREDITARY CREATINE TRANSPORTER DEFICIENCY; HIGH RISK PATIENT; IN VITRO STUDY; IN VIVO STUDY; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NEUROPROTECTION; NONHUMAN; OPEN HEART SURGERY; PRIORITY JOURNAL; PROTEIN DEFICIENCY; STROKE; TRANSIENT ISCHEMIC ATTACK;

ANIMALS; BRAIN INFARCTION; BRAIN ISCHEMIA; CREATINE; CYTOPROTECTION; DISEASE MODELS, ANIMAL; INFARCTION, MIDDLE CEREBRAL ARTERY; MAGNESIUM; MALE; MEMBRANE TRANSPORT PROTEINS; MICE; NERVE DEGENERATION; NEUROPROTECTIVE AGENTS; PHOSPHOCREATINE; TREATMENT OUTCOME;

MUS;

EID: 67651180519     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.brainres.2009.06.009     Document Type: Article

References (24)

1. Banks J.L., and Marotta C.A. Outcomes validity and reliability of the modified Rankin scale: implications for stroke clinical trials: a literature review and synthesis. Stroke 38 (2007) 1091-1096
2. Battini R., Alessandri M.G., Leuzzi V., Moro F., Tosetti M., Bianchi M.C., and Cioni G. Arginine:glycine amidinotransferase (AGAT) deficiency in a newborn: early treatment can prevent phenotypic expression of the disease. J. Pediatr. 148 (2006) 828-830
3. Braun J.S., Prass K., Dirnagl U., Meisel A., and Meisel C. Protection from brain damage and bacterial infection in murine stroke by the novel caspase-inhibitor Q-VD-OPH. Exp. Neurol. 206 2 (2007) 183-191
4. Campbell K., Meloni B.P., and Knuckey N.W. Combined magnesium and mild hypothermia (35 degrees C) treatment reduces infarct volumes after permanent middle cerebral artery occlusion in the rat at 2 and 4, but not 6 h. Brain Res. 1230 (2008) 258-264
5. Clark W.M., Lessov N.S., Dixon M.P., and Eckenstein F. Microfilament intraluminal middle cerebral artery occlusion in the mouse. Neurol. Res. Dec. 19 6 (1997) 641-648
6. Connolly Jr. E.S., Winfree C.J., Rampersad A., Sharma R., Mack W.J., Mocco J., Solomon R.A., Todd G., Quest D.O., Stern Y., and Heyer E.J. Serum S100B protein levels are correlated with subclinical neurocognitive declines after carotidendarterectomy. Neurosurgery 49 (2001) 1076-1082
7. Degrauw T.J., Cecil K.M., Byars A.W., Salomons G.S., Ball W.S., and Jakobs C. The clinical syndrome of creatine transporter deficiency. Mol. Cell Biochem. 244 (2003) 45-48
8. Lensman M., Korzhevskii D.E., Mourovets V.O., Kostkin V.B., Izvarina N., Perasso L., Gandolfo C., Otellin V.A., Polenov S.A., and Balestrino M. Intracerebroventricular administration of creatine protects against damage by global cerebral ischemia in rat. Brain Res. 1114 (2006) 187-194
9. Lisabeth L.D., Ireland J.K., Risser J.M.H., Brown D.L., Smith M.A., Garcia N.M., and Morgenstern L.B. Stroke risk after transient ischemic attack in a population-based setting. Stroke 35 (2004) 1842-1846
10. Lunardi G., Parodi A., Perasso L., Pohvozcheva A.V., Scarrone S., Adriano E., Florio T., Gandolfo C., Cupello A., Burov S.V., and Balestrino M. The creatine transporter mediates the uptake of creatine by brain tissue, but not the uptake of two creatine-derived compounds. Neuroscience 142 (2006) 991-997
11. Meisel C., Schwab JM., Prass K., Meisel A., and Dirnagl U. Central nervous system injury-induced immune deficiency syndrome. Nat. Rev. Neurosci. 6 10 (2005) 775-786
12. Mercimek-Mahmutoglu S., Stoeckler-Ipsiroglu S., Adami A., Appleton R., Araujo H.C., Duran M., Ensenauer R., Fernandez-Alvarez E., Garcia P., Grolik C., Item C.B., Leuzzi V., Marquardt I., Muhl A., Saelke-Kellermann R.A., Salomons G.S., Schulze A., Surtees R., Van Der Knaap M.S., Vasconcelos R., Verhoeven N.M., Vilarinho L., Wilichowski E., and Jakobs C. GAMT deficiency: features, treatment, and outcome in an inborn error of creatine synthesis. Neurology 67 (2006) 480-484
13. Motulsky H. Prism 4 Statistics Guide - Statistical Analyses for Laboratory and Clinical Researchers (2003), GraphPad Software Inc., San Diego CA. http://www.graphpad.com (www.graphpad.com)
14. Newman M.F., Kirchner J.L., Phillips-Bute B., Gaver V., Grocott H., Jones R.H., Mark D.B., Reves J.G., and Blumenthal J.A. Longitudinal assessment of neurocognitive function after coronary-artery bypass surgery. N. Engl. J. Med. 344 (2001) 395-402
15. Ohtsuki S., Tachikawa M., Takanaga T., Shimizu H., Watanabe T.M., Hosoya K., and Terasaki T. The blood-brain barrier creatine transporter is a major pathway for supplying creatine to the brain. J. Cereb. Blood Flow Metab. 22 (2002) 1327-1335
16. Perasso L., Cupello A., Lunardi G., Principato C., Gandolfo C., and Balestrino M. Kinetics of creatine in blood and brain after intraperitoneal injection in the rat. Brain Res. 974 (2003) 37-42
17. Perasso L., Lunardi G., Risso F., Pohvozcheva A., Leko M., Gandolfo C., Florio T., Cupello A., Burov S., and Balestrino M. Protective effects of some creatine derivatives in brain tissue anoxia. Neurochem. Res. 33 (2008) 765-775
18. Prabhakar G., Vona D.L., Murray D., Lakhani P., and Murray G. Phosphocreatine restores high-energy phosphates in ischemic myocardium: implication for off-pump cardiac revascularization. J. Am. Coll. Surg. 197 (2003) 786-791
19. Prass K., Meisel C., Hoflich C., Braun J., Halle E., Wolf T., Ruscher K., Victorov IV., Priller J., Dirnagl U., Volk HD., and Meisel A. Stroke-induced immunodeficiency promotes spontaneous bacterial infections and is mediated by sympathetic activation reversal by poststroke T helper cell type 1-like immunostimulation. J. Exp. Med. 198 5 (2003) 725-736
20. Prass K., Royl G., Lindauer U., Freyer D., Megow D., Dirnagl U., Stockler-Ipsiroglu G., Wallimann T., and Priller J. Improved reperfusion and neuroprotection by creatine in a mouse model of stroke. J. Cereb. Blood Flow Metab. 27 3 (2007) 452-459
21. Salomons G.S., Van Dooren S.J., Verhoeven N.M., Cecil K.M., Ball W.S., Degrauw T.J., and Jacobs C. X linked creatine-transporter gene (SLC6A8) defect a new creatine-deficiency syndrome. Am. J. Hum. Genet. 68 5 (2001) 1497-1500
22. Salomons G., Van Dooren S., Verhoeven N., Marsden D., Schwartz C., Cecil K., DeGrauw T., and Jakobs C. X-linked creatine transporter defect: an overview. J. Inherit. Metab. Dis. 26 (2003) 309-318
23. Sharov V.G., Afonskaya N.I., Ruda M.Y., Cherpachenko N.M., Pozin E.Y., Markosyan R.A., Shepeleva I.I., Samarenko M.B., and Saks V.A. Protection of ischemic myocardium by exogenous phosphocreatine (neoton): pharmacokinetics of phosphocreatine, reduction of infarct size, stabilization of sarcolemma of ischemic cardiomyocytes, and antithrombotic action. Biochem. Med. Metab. Biol. 35 (1986) 101-114
24. Zhu S., Li M., Figueroa B.E., Liu A., Stavrovskaya I.G., Pasinelli P., Beal M.F., Brown Jr. R.H., Kristal B.S., Ferrante R.J., and Friedlander R.M. Prophylactic creatine administration mediates neuroprotection in cerebral ischemia in mice. J. Neurosci. 24 (2004) 5909-5912